given on the report forms and instructions.

(a) *Response required.* A response is required from persons subject to the reporting requirements of the BE–13, Survey of New Foreign Direct Investment in the United States, contained herein, whether or not they are contacted by BEA. Also, a person, or their agent, who is contacted by BEA about reporting in this survey, either by sending them a report form or by written inquiry, must respond in writing pursuant to this section. This may be accomplished by filing the properly completed BE–13 report (BE–13A, BE–13B, BE–13D, BE–13E, or BE–13 Claim for Exemption).

(b) *Who must report.* A BE–13 report is required of any U.S. business enterprise, except certain private funds, see exception in paragraph (b)(4) of this section, in which:

(1) A foreign direct investment in the United States relationship is created;

(2) An existing U.S. affiliate of a foreign parent establishes a new U.S. business enterprise, expands its U.S. operations, or acquires a U.S. business enterprise; or

(3) BEA requests a cost update (Form BE–13E) for a U.S. business enterprise that previously filed Form BE–13B or BE–13D.

(4) Certain private funds are exempt from reporting on the BE–13 survey. If a U.S. business enterprise is a private fund and does not own, directly or indirectly, 10 percent or more of another business enterprise that is not also a private fund or a holding company, it is not required to file any BE–13 report except to indicate exemption from the survey if contacted by BEA.

(c) *Forms to be filed.* Depending on the type of investment transaction, U.S. affiliates would report their information on one of five forms—BE–13A, BE–13B, BE–13D, BE–13E, or BE–13 Claim for Exemption.

(1) Form BE–13A—report for a U.S. business enterprise when a foreign entity acquires a voting interest (directly, or indirectly through an existing U.S. affiliate) in that U.S. business enterprise including segments, operating units, or real estate; and

(i) The total cost of the acquisition is greater than $3 million; and

(ii) By this acquisition, the foreign entity now owns at least 10 percent of the voting interest (directly, or indirectly through an existing U.S. affiliate) in the acquired U.S. business enterprise.

(2) Form BE–13B—report for a U.S. business enterprise when it is established by a foreign entity or by an existing U.S. affiliate of a foreign parent; and

(i) The expected total cost to establish the new U.S. business enterprise is greater than $3 million; and

(ii) The foreign entity owns at least 10 percent of the voting interest (directly, or indirectly through an existing U.S. affiliate) in the new U.S. business enterprise.

(3) Form BE–13D—report for an existing U.S. affiliate of a foreign parent when it expands its operations to include a new facility where business is conducted, and the expected total cost of the expansion is greater than $3 million.

(4) Form BE–13E—report for a U.S. business enterprise that previously filed Form BE–13B or BE–13D. Form BE–13E collects updated cost information and will be collected annually for three years after the year of the establishment or expansion of the U.S. business enterprise.

(5) Form BE–13 Claim for Exemption—report for a U.S. business enterprise that:

(i) Was contacted by BEA but does not meet the requirements for filing Forms BE–13A, BE–13B, or BE–13D; or

(ii) Whether or not contacted by BEA, met all requirements for filing Forms BE–13A, BE–13B, or BE–13D except the $3 million reporting threshold.

(d) *Due date.* The BE–13 forms are due no later than 45 calendar days after the acquisition is completed, the new U. S. business enterprise is established, the expansion is begun, the cost update is requested, or a notification letter is received from BEA by a U.S. business enterprise that does not meet the filing requirements for the survey.

[FR Doc. 2022–21116 Filed 9–28–22; 8:45 am]

BILLING CODE 3510–06–P

SECURITIES AND EXCHANGE COMMISSION

17 CFR Part 227

Regulation Crowdfunding, General Rules and Regulations

CFR Correction

This rule is being published by the Office of the Federal Register to correct an editorial or technical error that appeared in the most recent annual revision of the Code of Federal Regulations.

■ In Title 17 of the Code of Federal Regulations, Parts 200 to 239, revised as of April 1, 2022, amend § 227.201 by adding paragraph (z) to read as follows:

§ 227.201 Disclosure requirements.

* * * * *

(z) Any written communication or broadcast script provided in accordance with § 227.206 or, if within 30 days of the initial filing of the offering statement, § 230.241 of this chapter.

* * * * *

[FR Doc. 2022–21290 Filed 9–28–22; 8:45 am]

BILLING CODE 0099–10–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 515, 516, 520, 522, 524, 529, and 558

[Docket No. FDA–2022–N–0002]

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Name and Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January, February, and March 2022. FDA is informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to improve the accuracy of the regulations.

DATES: This rule is effective September 29, 2022.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–402–5689, *george.haibel@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Approvals

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January, February, and March 2022, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring

review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the office of the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: *https://www.fda.gov/about-fda/center-veterinary-medicine/cvm-foia-electronic-reading-room*. Marketing exclusivity and patent information may be accessed in FDA's publication, ''Approved Animal Drug Products Online (Green Book)'' at: *https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book.*

FDA has verified the website addresses as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING JANUARY, FEBRUARY, AND MARCH 2022

Approval date	File No.	Sponsor	Product name	Species	Effect of the action	Public documents
January 10, 2022	131–675	Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940.	SAFE–GUARD (fenbendazole), Type A Medicated Article.	Cattle	Supplemental approval to establish withdrawal periods in accordance with repartitioning of acceptable daily intake; and to add fourth-stage larval indications for certain endoparasites of cattle.	
January 13, 2022	141–546	Zoetis Inc, 333 Portage St., Kalamazoo, MI 49007.	SOLENSIA (frunevetmab injection), Injectable Solution.	Cats	Original approval for the control of pain associated with osteoarthritis.	FOI Summary.
January 20, 2022	141–547	Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140.	ZORBIUM (buprenorphine transdermal solution), Transdermal Solution.	Cats	Original approval for the control of postoperative pain associated with surgical procedures.	FOI Summary.
January 25, 2022	200–707	Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str.,1113 Sofia, Bulgaria.	TILMOVET AC (tilmicosin), Solution.	Swine	Original approval as a generic copy of NADA 141–361.	FOI Summary.
January 28, 2022	200–716	Norbrook Laboratories Ltd., Carnbane Industrial Estate, Newry, County Down, BT35 6QQ, United Kingdom.	MIDAMOX for Dogs (imidacloprid and moxidectin), Topical Solution.	Dogs	Original approval as a generic copy of NADA 141–251.	FOI Summary.
February 7, 2022	200–665	Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140.	INCREXXA 25 (tulathromycin injection), Injectable Solution.	Cattle and Swine.	Original approval as a generic copy of NADA 141–349.	FOI Summary.
February 7, 2022	200–717	Aurora Pharmaceutical, Inc,1196 Highway 3 South, Northfield, MN 55057–3009.	TIAGARD 12.5% (tiamulin hydrogen fumarate), Liquid Concentrate.	Swine	Original approval as a generic copy of NADA 140–916.	FOI Summary.
February 7, 2022	200–718	.....do	BARRIER for Dogs (imidacloprid and moxidectin), Topical Solution.	Dogs	Original approval as a generic copy of NADA 141–251.	FOI Summary.
February 9, 2022	200–715	Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940.	AROVYN (tulathromycin injection), Injectable Solution.	Cattle and Swine.	Original approval as a generic copy of NADA 141–244.	FOI Summary.
March 11, 2022	200–720	Norbrook Laboratories Ltd., Carnbane Industrial Estate, Newry, County Down, BT35 6QQ, United Kingdom.	ENROFLOX (enrofloxacin), Chewable Tablets.	Dogs	Original approval as a generic copy of NADA 140–441.	FOI Summary.
March 23, 2022	200–723	.....do	TULIEVE (tulathromycin injection), Injectable Solution.	Cattle and Swine.	Original approval as a generic copy of NADA 141–244.	FOI Summary.
March 28, 2022	200–721	.....do	MIDAMOX for Cats (imidacloprid and moxidectin), Topical Solution.	Cats	Original approval as a generic copy of NADA 141–254.	FOI Summary.
March 28, 2022	200–722	.....do	FIROX (firocoxib), Chewable Tablets.	Dogs	Original approval as a generic copy of NADA 141–230.	FOI Summary.
March 28, 2022	200–688	Virbac AH, Inc., P.O .Box 162059, Fort Worth, TX 76161.	TENOTRYL (enrofloxacin), Injectable Solution.	Cattle and Swine.	Original approval as a generic copy of NADA 141–068.	FOI Summary.
March 30, 2022	141–551	Vetcare Oy, P.O. Box 26 (Liedontie 45), Mäntsälä, Uusimaa, 04601, Finland.	ZENALPHA (medetomidine and vatinoxan injection).	Dogs	Original approval for use as a sedative and analgesic to facilitate clinical examination, clinical procedures, and minor surgical procedures.	FOI Summary.

II. Withdrawals of Approval

Lloyd, Inc., 604 W. Thomas Ave., Shenandoah, IA 51601, has requested that FDA withdraw approval of NADA 140–908 for VET–METH Bolus, a bolus containing sulfamethazine for use in cattle because the product is no longer manufactured or marketed. As provided in the regulatory text of this document, the animal drug regulations in 21 CFR 520.2260a are amended to reflect this action.

Ridley USA, Inc., 111 W. Cherry St., Suite 500, Mankato, MN 56001, has requested that FDA withdraw approval of NADA 136–214 for VMS Bloat Blox, an oral dosage form containing polyoxyethylene (23) lauryl ether for use in beef and nonlactating dairy cattle because the product is no longer manufactured or marketed. As provided in the regulatory text of this document, the animal drug regulations in 21 CFR 520.1846 are amended to reflect this action.

III. Changes of Sponsorship

Halocarbon Products Corp., 6525 The Corners Pkwy., Suite 200, Peachtree Corners, GA 30092 has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200–129 for Isoflurane, USP and ANADA 200–467 for Sevoflurane to Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211. As provided in the regulatory text, the animal drug regulations in 21 CFR 529.1186 and 529.2110, respectively, are amended to reflect these changes of sponsorship.

IV. Change of Sponsor's Name and Address

Mylan Institutional, Inc., 12720 Dairy Ashford Rd., Sugar Land, TX 77478 has informed FDA that it has changed its name and address to Mylan Institutional, Inc., a Viatris Company, 3711 Collins Ferry Rd., Morgantown, WV 26505. As provided in the regulatory text, the animal drug regulations in § 510.600(c) (21 CFR 510.600(c)) are amended to reflect this change of a sponsor's name and address.

V. Technical Amendments

FDA is making the following amendments to improve the accuracy of the animal drug regulations:

- Section 510.600 is amended to remove the entry for Halocarbon Products Corp. from, and add Vetcare Oy to, the list of sponsors of approved applications. The entries for Mylan Institutional, Inc. and Norbrook Laboratories Ltd. are revised as well.
- 21 CFR 516.812 is amended to reflect a current drug labeler code for a use of enrofloxacin injectable solution in cattle.
- 21 CFR 520.88g is amended reflect a current sponsor drug labeler code and revised indications for use of tablets containing amoxicillin and clavulanate in dogs and cats.
- 21 CFR 520.530 is amended to conform to content codified for animal drugs available by veterinary prescription.
- 21 CFR 520.905a is amended to reflect revised conditions of use for fenbendazole suspension in horses.
- 21 CFR 520.928 is amended to reflect correct directions for administration of firocoxib chewable tablets in dogs.
- 21 CFR 520.1242a is amended to reflect revised indications for use of a levamisol powder in cattle and sheep.
- 21 CFR 520.1720a is amended to correct an error in the strength of approved phenylbutazone boluses.
- 21 CFR 520.1870 is amended to remove an undefined acronym in the conditions for use of praziquantel tablets.
- 21 CFR 520.1872 is amended to conform to content codified for animal drugs available by veterinary prescription.
- 21 CFR 520.2325a is amended to reflect instructions for use of sulfaquinoxaline powder and solution in poultry and cattle.
- 21 CFR 520.2598 is amended to reflect revised indications for use for trilostane capsules in dogs.
- 21 CFR 522.533 is amended to revise the indications for use of deslorelin injectable solution in mares.
- 21 CFR 522.2615 is amended to reflect revised human food safety warnings for tripelennamine injectable solution in cattle.
- 21 CFR 524.1001 is amended to correct a spelling error in the heading and specifications for fluralaner and moxidectin topical solution.
- 21 CFR 524.2098 is amended to reflect all sponsors of approved applications for selamectin topical solution in dogs and cats.
- 21 CFR 558.4 is amended in the Category II table to reflect the correct assay limits for Type C medicated feeds manufactured using nicarbazin powder.
- 21 CFR 558.128 is amended to reflect the class of cattle and incorporation level for single-ingredient and combination-drug medicated feeds containing chlortetracycline used for control of anaplasmosis in cattle.
- 21 CFR 558.633 is amended to clarify expiration dates for medicated feeds containing tylvalosin.

VI. Legal Authority

This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)), which requires **Federal Register** publication of ''notice[s]. . . effective as a regulation,'' of the conditions of use of approved new animal drugs. This rule sets forth technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities.

Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a ''rule of particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as ''an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.''

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 515 and 516

Administrative practice and procedure, Animal drugs, Confidential business information, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, 524, and 529

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 515, 516, 520, 522, 524, 529, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600:

■ a. In the table in paragraph (c)(1), remove the entry for ''Halocarbon

Products Corp.''; revise the entries for ''Mylan Institutional, Inc.'' and ''Norbrook Laboratories Ltd.''; and add in alphabetical order an entry for ''Vetcare Oy''; and

■ b. In the table in paragraph (c)(2), remove the entry for ''012164''; revise the entries for ''051079'' and ''055529''; and add in numerical order an entry for ''086155''.

The revisions and additions read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * * * * * *	
Mylan Institutional, Inc., a Viatris Company, 3711 Collins Ferry Rd., Morgantown, WV 26505	051079
* * * * * * *	
Norbrook Laboratories Ltd., Carnbane Industrial Estate, Newry, County Down, BT35 6QQ, United Kingdom	055529
* * * * * * *	
Vetcare Oy, P.O. Box 26 (Liedontie 45), Mäntsälä, Uusimaa, 04601, Finland	086155
* * * * * * *	

(2) * * *

Drug labeler code	Firm name and address
* * * * * * *	
051079	Mylan Institutional, Inc., a Viatris Company, 3711 Collins Ferry Rd., Morgantown, WV 26505.
* * * * * * *	
055529	Norbrook Laboratories Ltd., Carnbane Industrial Estate, Newry, County Down, BT35 6QQ, United Kingdom.
* * * * * * *	
086155	Vetcare Oy, P.O. Box 26 (Liedontie 45), Mäntsälä, Uusimaa, 04601, Finland.
* * * * * * *	

PART 515—MEDICATED FEED MILL LICENSE

■ 3. The authority citation for part 515 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

■ 4. In § 515.10, revise paragraph (a) to read as follows:

§ 515.10 Medicated feed mill license applications.

(a) Medicated feed mill license applications (Form FDA 3448) may be obtained from the Public Health Service, Consolidated Forms and Publications Distribution Center, Washington Commerce Center, 3222 Hubbard Rd., Landover, MD 20785, or electronically from the Center for Veterinary Medicine at: *https://www.fda.gov/animal-veterinary/animal-food-feeds/medicated-feeds.*

* * * * *

PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES

■ 5. The authority citation for part 516 continues to read as follows:

Authority: 21 U.S.C. 360ccc–1, 360ccc–2, 371.

§ 516.812 [Amended]

■ 6. In § 516.812, in paragraph (b), remove ''000859'' and in its place add ''058198''.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 7. The authority citation for part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 8. In § 520.88g, revise paragraphs (b)(2), (c)(1)(ii), and (c)(2)(ii) to read as follows:

§ 520.88g Amoxicillin trihydrate and clavulanate potassium tablets.

* * * * *

(b) * * *

(2) Nos. 017033 and 069043 for use of tablets as in paragraph (c) of this section.

(c) * * *

(1) * * *

(ii) *Indications for use.* Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: Beta-lactamase-producing *Staphylococcus aureus,* non-beta-lactamase-producing *Staphylococcus aureus, Staphylococcus* spp., *Streptococcus* spp., and *E. coli.* Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

* * * * *

(2) * * *

(ii) *Indications for use.* Treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: Beta-lactamase-producing *Staphylococcus aureus,* non-beta-lactamase-producing *Staphylococcus aureus, Staphylococcus* spp., *Streptococcus* spp., *E. coli,* and *Pasteurella* spp. Urinary tract infections (cystitis) due to susceptible strains of *E. coli.*

* * * * *

§ 520.530 [Amended]

■ 9. In § 520.530, remove paragraph (c) and redesignate paragraph (d) as paragraph (c).

■ 10. In § 520.812, revise paragraphs (b)(1) and (3) to read as follows:

§ 520.812 Enrofloxacin.

* * * * *

(b) * * *

(1) No. 058198 for use of products described in paragraph (a) of this section.

* * * * *

(3) Nos. 055529 and 086101 for use of product described in paragraph (a)(2) of this section.

* * * * *

■ 11. In § 520.905a, revise paragraphs (e)(1)(ii) and (iii) to read as follows:

§ 520.905a Fenbendazole suspension.

* * * * *

(e) * * *

(1) * * *

(ii) *Indications for use.* For the treatment and control of large strongyles (*Strongylus edentatus, S. equinus, S. vulgaris, Triodontophorus* species), small strongyles (*Cyathostomum* species, *Cylicocyclus* species, *Cylicostephanus* species, *Cylicodontophorus* species), pinworms (*Oxyuris equi*) and ascarids (*Parascaris equorum*).

(iii) *Limitations.* Do not use in horses intended for human consumption.

* * * * *

■ 12. In § 520.928, revise the section heading and paragraphs (a), (b), and (c)(1)(i) to read as follows:

§ 520.928 Firocoxib.

(a) *Specifications*—(1) Each chewable tablet contains 57 or 227 milligrams (mg) firocoxib.

(2) Each tablet contains 57 mg firocoxib.

(b) *Sponsors.* See sponsors in § 510.600(c) of this chapter as follows:

(1) Nos. 000010 and 055529 for use of products described in paragraph (a)(1) as in paragraph (c)(1) of this section; and

(2) No. 000010 for use of the product described in paragraph (a)(2) as in paragraph (c)(2) of this section.

(c) * * *

(1) * * *

(i) *Amount.* 5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft tissue or orthopedic surgery.

* * * * *

■ 13. In § 520.1242a, revise paragraph (b)(3) to read as follows:

§ 520.1242a Levamisol powder.

* * * * *

(b) * * *

(3) No. 016592 for use of 46.8- and 544.5-g packages as in paragraphs (e)(1)(i), (e)(1)(ii)(B), and (e)(1)(iii) and (e)(2)(i), (e)(2)(ii)(B), and (e)(2)(iii) of this section.

* * * * *

■ 14. In § 520.1720a, revise paragraph (a) to read as follows:

§ 520.1720a Phenylbutazone tablets and boluses.

(a) *Specifications.* Each tablet contains 100, 200, or 400 milligrams (mg), or 1 gram (g) phenylbutazone. Each bolus contains 1, 2, or 4 g phenylbutazone.

* * * * *

§ 520.1846 [Removed]

■ 15. Remove § 520.1846.

§ 520.1870 [Amended]

■ 16. In § 520.1870, in paragraph (c)(2)(iii), in the third sentence, remove ''OTC'' and in its place add ''over the counter''.

■ 17. In § 520.1872, revise paragraph (c)(1)(iii) and add reserved paragraph (c)(2) to read as follows:

§ 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

* * * * *

(c) * * *

(1) * * *

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

■ 18. Revise § 520.2260a to read as follows:

§ 520.2260a Sulfamethazine oblets and boluses.

(a) *Specifications.* Each oblet or bolus contains:

(1) 2.5, 5, or 15 grams sulfamethazine.

(2) 5 grams sulfamethazine.

(b) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use of products described in paragraph (a) of this section.

(1) No. 016592 for use of products described in paragraph (a)(1) of this section.

(2) No. 054771 for use of product described in paragraph (a)(2) of this section.

(c) *Related tolerances.* See § 556.670 of this chapter.

(d) *Conditions of use.* (1) Oblets and boluses described in paragraph (a)(1) of this section:

(i) *Amount.* Administer as a single dose 100 milligrams per pound (mg/lb) of body weight the first day and 50 mg/lb of body weight on each following day.

(ii) *Indications for use.* (A) *Beef cattle and nonlactating dairy cattle.* For the treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (*Pasteurella* spp.), colibacillosis (bacterial scours) (*Escherichia coli*), necrotic pododermatitis (foot rot) (*Fusobacterium necrophorum*), calf diphtheria (*Fusobacterium necrophorum*), acute mastitis (*Streptococcus* spp.), acute metritis (*Streptococcus* spp.), and coccidiosis (*Eimeria bovis* and *E. zurnii*).

(B) *Horses.* For the treatment of bacterial pneumonia (secondary infections associated with *Pasteurella* spp.), strangles (*Streptococcus* equi), and bacterial enteritis (*Escherichia coli*).

(iii) *Limitations.* Administer daily until animal's temperature and appearance are normal. If symptoms persist after using for 2 or 3 days consult a veterinarian. Fluid intake must be adequate. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed 5 consecutive days. Follow dosages carefully. Do not treat cattle within 10 days of slaughter. Do not use in female dairy cattle 20 months of age or older. Use of sulfamethazine in this class of cattle may cause milk residues. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Do not use in horses intended for human consumption.

(2) Boluses described in paragraph (a)(2) of this section:

(i) *Amount.* Administer 10 grams (2 boluses) of sulfamethazine per 100 pounds of body weight the first day, then 5 grams (1 bolus) of sulfamethazine per 100 pounds of body weight daily for up to 4 additional consecutive days.

(ii) *Indications for use.* (A) *Ruminating beef and dairy calves.* For treatment of the following diseases caused by organisms susceptible to sulfamethazine: bacterial scours (colibacillosis) caused by *Escherichia coli;* necrotic pododermatitis (foot rot) and calf diphtheria caused by *Fusobacterium necrophorum;* bacterial pneumonia associated with *Pasteurella* spp.; and coccidiosis caused by *Eimeria bovis* and *E. zurnii.*

(B) [Reserved]

(iii) *Limitations.* Do not administer for more than 5 consecutive days. Do not treat calves within 11 days of slaughter. Do not use in calves to be slaughtered under 1 month of age or in calves being

fed an all milk diet. Do not use in female dairy cattle 20 months of age or older; such use may cause drug residues in milk. Administer with adequate supervision. Follow recommended dosages carefully. Fluid intake must be adequate. If symptoms persist after 2 or 3 days, consult a veterinarian.

■ 19. In § 520.2325a, revise paragraphs (c)(4)(iii) and (d) to read as follows:

§ 520.2325a Sulfaquinoxaline powder and solution.

* * * * *

(c) * * *

(4) * * *

(iii) In lieu of treatment as provided in paragraph (c)(4)(ii) of this section, administer 1 teaspoon of 25 percent sulfaquinoxaline soluble powder per day for each 125 pounds of body weight for 3 to 5 days in drinking water.

(d) *Limitations.* A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Not for use in lactating dairy cattle. Do not give to chickens, turkeys, or cattle within 10 days of slaughter for food. Do not medicate chickens or turkeys producing eggs for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

■ 20. In § 520.2455, revise paragraph (b)(3) to read as follows:

§ 520.2455 Tiamulin.

* * * * *

(b) * * *

(3) Nos. 016592, 051072, 051311, and 061133 for product described in paragraph (a)(2) of this section.

* * * * *

■ 21. In § 520.2471, revise paragraph (b) to read as follows:

§ 520.2471 Tilmicosin.

* * * * *

(b) *Sponsors.* See Nos. 016592 and 058198 in § 510.600(c) of this chapter.

* * * * *

■ 22. In § 520.2598, revise paragraph (c)(2) to read as follows:

§ 520.2598 Trilostane.

* * * * *

(c) * * *

(2) *Indications for use.* For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

* * * * *

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 23. The authority citation for part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 24. In § 522.533, revise paragraphs (c)(1)(ii) and (c)(2)(ii) to read as follows:

§ 522.533 Deslorelin.

* * * * *

(c) * * *

(1) * * *

(ii) *Indications for use.* For inducing ovulation within 48 hours in estrous mares with an ovarian follicle greater than 30 millimeters (mm) in diameter.

* * * * *

(c) * * *

(2) * * *

(ii) *Indications for use.* For inducing ovulation within 48 hours in cyclic estrous mares with an ovarian follicle between 30 and 40 mm in diameter.

* * * * *

■ 25. In § 522.812, revise paragraph (b)(2) to read as follows:

§ 522.812 Enrofloxacin.

* * * * *

(b) * * *

(2) Nos. 051311, 055529, 058005, 058198, and 061133 for use of product described in paragraph (a)(2) of this section as in paragraphs (e)(2) and (3) of this section.

* * * * *

■ 26. Add § 522.1008 to read as follows:

§ 522.1008 Frunevetmab.

(a) *Specifications.* Each milliliter (mL) of solution contains 7 milligrams (mg) frunevetmab.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Cats*—(i) *Amount.* Administer once a month by subcutaneous injection the full contents of one or two 1-mL vials to achieve a minimum dosage of 0.45 mg/lb (1 mg/kg) body weight.

(ii) *Indications for use.* For the control of pain associated with osteoarthritis in cats.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

■ 27. Add § 522.1338 to read as follows:

§ 522.1338 Medetomidine and vatinoxan.

(a) *Specifications.* Each milliliter of solution contains 0.5 milligrams (mg) medetomidine hydrochloride and 10 mg vatinoxan hydrochloride.

(b) *Sponsor.* See No. 086155 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Amount.* Administer by intramuscular injection a dose based on body surface area (BSA). Calculate the dose using 1 mg medetomidine per square meter ($/m^2$) BSA or use the dosing table provided in labeling.

(2) *Indications for use.* For use as a sedative and analgesic in dogs to facilitate clinical examination, clinical procedures, and minor surgical procedures.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

■ 28. In § 522.2615, revise paragraph (d)(3)(iii) to read as follows:

§ 522.2615 Tripelennamine.

* * * * *

(d) * * *

(3) * * *

(iii) *Limitations.* Milk taken during treatment and for 24 hours after the last treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 4 days following the last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

■ 29. In § 522.2630, revise paragraphs (b)(1) and (2) to read as follows:

§ 522.2630 Tulathromycin.

* * * * *

(b) * * *

(1) Nos. 000061, 013744, 051311, 054771, 055529, 058198, and 061133 for use of product described in paragraph (a)(1) as in paragraphs (d)(1)(i), (d)(1)(ii), (d)(1)(iii)(A), and (d)(2) of this section.

(2) Nos. 013744, 051311, 054771, and 058198 for use of product described in paragraph (a)(2) as in paragraphs (d)(1)(i), (d)(1)(ii)(B), (d)(1)(iii)(B), and (d)(2) of this section.

* * * * *

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

■ 30. The authority citation for part 524 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 31. Add § 524.230 to read as follows:

§ 524.230 Buprenorphine.

(a) *Specifications.* Each milliliter (mL) of solution contains 20 milligrams (mg) buprenorphine. The drug is supplied in tubes containing 0.4 mL (8 mg) or 1.0 mL (20 mg).

(b) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.

(c) *Conditions of use in cats*—(1) *Amount.* Administer topically to the dorsal cervical area at the base of the skull a single dose of 1.2 to 3.1 mg/lb

(2.7 to 6.7 mg/kg) approximately 1 to 2 hours before surgery.

(2) *Indications for use.* For the control of postoperative pain associated with surgical procedures in cats.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Buprenorphine is a Schedule III controlled substance.

■ 32. In § 524.1001, revise the section heading and paragraph (a) to read as follows:

§ 524.1001 Fluralaner and moxidectin.

(a) *Specifications.* Each milliliter of solution contains 280 milligram (mg) fluralaner and 14 mg moxidectin. Each individually packaged tube contains either 112.5 mg fluralaner and 5.6 mg moxidectin; 250 mg fluralaner and 12.5 mg moxidectin; or 500 mg fluralaner and 25 mg moxidectin.

* * * * *

■ 33. In § 524.1146, revise paragraphs (b)(1) and (2) to read as follows:

§ 524.1146 Imidacloprid and moxidectin.

* * * * *

(b) * * *

(1) Nos. 017030, 051072, 055529, 058198, and 061651 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section.

(2) Nos. 017030, 051072, 055529, 058198, and 061651 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.

* * * * *

■ 34. In § 524.2098, revise paragraph (b) to read as follows:

§ 524.2098 Selamectin.

* * * * *

(b) *Sponsors.* See Nos. 051072, 054771, 055529, 061133, and 061651 in § 510.600(c) of this chapter.

* * * * *

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

■ 35. The authority citation for part 529 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 36. In § 529.1186, revise paragraph (b) to read as follows:

§ 529.1186 Isoflurane.

* * * * *

(b) *Sponsors.* See Nos. 017033, 054771, 065085, and 066794 in § 510.600(c) of this chapter.

* * * * *

■ 37. In § 529.2110, revise paragraph (b) to read as follows:

§ 529.2110 Sevoflurane.

* * * * *

(b) *Sponsors.* See Nos. 017033, 054771, and 066794 in § 510.600(c) of this chapter.

* * * * *

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 38. The authority citation for part 558 continues to read as follows:

Authority: 21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371.

■ 39. In § 558.4, in paragraph (d), in the ''Category II'' table, revise the entry for ''Nicarbazin (powder)'' to read as follows:

§ 558.4 Requirement of a medicated feed mill license.

* * * * *

(d) * * *

CATEGORY II

Drug	Assay limits percent [1] type A	Type B maximum (100x)	Assay limits percent [1] type B/C [2]
* * *	*	* * *	*
Nicarbazin (powder)	96–104	9.08 g/lb (2.00%)	85–115/80–120
* * *	*	* * *	*

* * * * * * *.

* * * * *

■ 40. In § 558.128, revise paragraphs (e)(4)(iii) and (xli) to read as follows:

§ 558.128 Chlortetracycline.

* * * * *

(e) * * *

(4) * * *

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
* * *	*	* *	*	*
(iii) to provide 0.5 mg/lb of body weight daily.		Beef cattle (over 700 lb): For control of active infection of anaplasmosis caused by *Anaplasma marginale* susceptible to chlortetracycline.	Feed to provide chlortetracycline at the rate of 0.5 mg per pound of body weight daily. Withdraw 48 hours prior to slaughter. To sponsor Nos. 054771 and 069254: Zero withdrawal time.	054771 066104 069254

Chlortetracycline amount	Combination in grams/ton	Indications for use	Limitations	Sponsor
* * *	*	* *	*	*
(xli) 25 to 2,800 g/ton to provide 350 mg/head/day.	Lasalocid, 30 to 181.8; melengestrol acetate, 0.25 to 2 g/ton to provide 0.25 to 0.5 mg/head/day melengestrol acetate.	Growing beef heifers fed in confinement for slaughter under 700 pounds: For control of active infection of anaplasmosis caused by *Anaplasma marginale* susceptible to chlortetracycline, control of coccidiosis caused by *Eimeria bovis* and *E. zuernii,* increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).	The melengestrol acetate Type C top-dress medicated feed must be top dressed onto or mixed at feeding with a Type C medicated feed containing 25 to 2,800 g/ton of chlortetracycline and 30 to 181.8 g/ton lasalocid to provide 350 mg chlortetracycline per head per day and 1 mg lasalocid per 2.2 lb. of body weight daily with a maximum of 360 mg lasalocid per head per day. See § 558.311(d) of this chapter. Chlortetracycline, lasalocid, and melengestrol as provided by No. 054771 in § 510.600(c) of this chapter.	054771
* * *	*	* *	*	*

* * * * * * *.

* * * * *

■ 41. In § 558.258, revise paragraph (e)(1), paragraph (e)(2) table column headings, and paragraphs (e)(2)(i) and (e)(3) through (5) to read as follows:

§ 558.258 Fenbendazole.

* * * * *

(e) * * *

(1) * * *

Fenbendazole grams per ton	Combination grams per ton	Indications for use	Limitations	Sponsor
(i) 14.5		Growing turkeys: For the treatment and control of gastrointestinal worms: roundworms, adults and larvae (*Ascaridia dissimilis*); cecal worms, adults and larvae (*Heterakis gallinarum*), an important vector of *Histomonas meleagridis* (Blackhead).	Feed continuously as the sole ration for 6 days. For growing turkeys only.	000061
(ii) [Reserved]				

(2) *Swine.*

Fenbendazole grams per ton	Combination grams per ton	Indications for use	Limitations	Sponsor
(i) 10 to 300		Swine: For the treatment and control of Lungworms: adult (*Metastrongylus apri* and *M. pudendotectus*); Gastrointestinal worms: adult and larvae (L3, 4 stages—liver, lung, intestinal forms) large roundworms (*Ascaris suum*); adult nodular worms (*Oesophagostomum dentatum, O. quadrispinulatum*); adult small stomach worms (*Hyostrongylus rubidus*); adult and larvae (L2, 3, 4 stages—intestinal mucosal forms) whipworms (*Trichuris suis);* and Kidney worms: adult and larvae (*Stephanurus dentatus*).	Feed as the sole ration to provide 9 mg/kg of body weight (4.08 mg/lb) over a period of 3 to 12 consecutive days. Swine must not be slaughtered for human consumption within 4 days following last treatment with this drug product.	000061
*	*	*	*	*	*	*

(3) *Cattle.*

Fenbendazole grams per ton	Indications for use	Limitations	Sponsor
(i) 200 to 1,000	Dairy and beef cattle: For the treatment and control of: Lungworms: adult (*Dictyocaulus viviparus*); Stomach worms: adult brown stomach worms (*Ostertagia ostertagi*), adult and fourth-stage larvae barberpole worms (*Haemonchus contortus*), fourth-stage larvae barberpole worms (*H. placei*), and adult and fourth-stage larvae small stomach worms (*Trichostrongylus axei*); Intestinal worms (adult and fourth-stage larvae): hookworms (*Bunostomum phlebotomum*), thread-necked intestinal worms (*Nematodirus helvetianus*), small intestinal worms (*Cooperia punctata* and *C. oncophora*), bankrupt worms (*Trichostrongylus colubriformis*), and nodular worms (*Oesophagostomum radiatum*).	Feed as the sole ration for 1 day to provide 5 mg/kg body weight (2.27 mg/lb). Milk taken during treatment and for 60 hours after the last treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 13 days following last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.	000061
(ii) [Reserved]			

(iii) *Top dress medicated feed*—(A) *Proprietary formulas.* The following feed can be manufactured only per an approved proprietary formula and specifications:

Fenbendazole concentration	Indications for use	Limitations	Sponsor
(*1*) 2.27 g/lb	Beef and dairy cattle: For the treatment and control of: Lungworms: adult (*Dictyocaulus viviparus*); Stomach worms: adult brown stomach worms (*Ostertagia ostertagi*), adult and fourth-stage larvae barberpole worms (*Haemonchus contortus*), fourth-stage larvae barberpole worms (*H. placei*), and adult and fourth-stage larvae small stomach worms (*Trichostrongylus axei*); Intestinal worms (adult and fourth-stage larvae): hookworms (*Bunostomum phlebotomum*), thread-necked intestinal worms (*Nematodirus helvetianus*), small intestinal worms (*Cooperia punctata and C. oncophora*), bankrupt worms (*Trichostrongylus colubriformis*), and nodular worms (*Oesophagostomum radiatum*).	Feed as a top dress for 1 day to provide 5 mg/kg body weight (2.27 mg/lb). Milk taken during treatment and for 60 hours after the last treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 13 days following last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.	000061
(*2*) [Reserved]			

(B) [Reserved]

(iv) *Free-choice medicated feeds*—(A) *Proprietary formulas (21 CFR 510.455(e)(2)).* The following feeds can be manufactured only per an approved proprietary formula and specifications:

Fenbendazole concentration	Indications for use	Limitations	Sponsor
(*1*) 12,100 g/ton mineral	Beef cattle on pasture: For the treatment and control of: Lungworms: adult (*Dictyocaulus viviparus*); Stomach worms: adult brown stomach worms (*Ostertagia ostertagi*), adult and fourth-stage larvae barberpole worms (*Haemonchus contortus*), fourth-stage larvae barberpole worms (*H. placei*), and adult and fourth-stage larvae small stomach worms (*Trichostrongylus axei*); Intestinal worms (adult and fourth-stage larvae): hookworms (*Bunostomum phlebotomum*), thread-necked intestinal worms (*Nematodirus helvetianus*), small intestinal worms (*Cooperia punctata* and *C. oncophora*), bankrupt worms (*Trichostrongylus colubriformis*), and nodular worms (*Oesophagostomum radiatum*).	Feed free-choice at the rate of 0.0375 lb per 100 pounds of body weight over a 3- to 6-day period to provide a total of 2.27 mg fenbendazole per pound of body weight. Not for use in dairy cattle. Beef cattle must not be slaughtered for human consumption within 13 days following last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.	000061
(*2*) 2.27 g/lb mineral	Beef cattle on pasture: For the treatment and control of: Lungworms: adult (*Dictyocaulus viviparus*); Stomach worms: adult brown stomach worms (*Ostertagia ostertagi*), adult and fourth-stage larvae barberpole worms (*Haemonchus contortus*), fourth-stage larvae barberpole worms (*H. placei*), and adult and fourth-stage larvae small stomach worms (*Trichostrongylus axei*); Intestinal worms (adult and fourth-stage larvae): hookworms (*Bunostomum phlebotomum*), thread-necked intestinal worms (*Nematodirus helvetianus*), small intestinal worms (*Cooperia punctata* and *C. oncophora*), bankrupt worms (*Trichostrongylus colubriformis*), and nodular worms (*Oesophagostomum radiatum*).	Feed free-choice at the rate of 0.10 lb (1.6 oz) per 100 pounds of body weight over a 3- to 6-day period, to deliver a total of 2.27 mg fenbendazole per pound of body weight. Not for use in dairy cattle. Beef cattle must not be slaughtered for human consumption within 13 days following last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.	000061

(B) *Published formulas (§ 510.455(e)(1) of this chapter).* The following feeds can be manufactured only per one of the formulas and specifications published below:

(*1*) *Amount.* 5 mg/kg body weight (2.27 mg/lb), including the following formulations:

Ingredient [1]	Percent	International Feed No.
(*i*) Free-choice, dry Type C feed:		
Salt (sodium chloride)	59.00	6–04–152
Monosodium phosphate	31.16	6–04–288
Dried cane molasses	3.12	4–04–695
Zinc sulfate	0.76	6–05–556
Copper sulfate	0.45	6–01–720
Fenbendazole 20% Type A article	5.51	n/a
(*ii*) Free-choice, dry Type C feed:		
Salt (sodium chloride)	35.93	6–04–152
Dicalcium phosphate (18.5% P)	32.44	6–00–080
Calcium carbonate (38% Ca)	15.93	6–01–069
Magnesium oxide (56% Mg)	10.14	6–02–756
Zinc sulfate	1.47	6–05–556
Mineral oil	1.00	8–03–123
Dried cane molasses (46% sugars)	0.98	4–04–695
Potassium iodide	0.01	6–03–759
Fenbendazole 20% Type A article	2.10	n/a
(*iii*) Free-choice, liquid Type C feed [2]:		
Cane molasses [3]	80.902	4–13–251
Water	9.36	n/a
Urea solution, 55%	7.05	5–05–707
Phosphoric acid 75% (feed grade)	2.00	6–03–707
Xantham gum	0.20	8–15–818
Trace minerals [4]	0.20	n/a
Vitamin premix [4]	0.01	n/a
Fenbendazole 20% Type A article	0.278	n/a

[1] Formulation modifications require FDA approval prior to marketing. Selenium is not approved for use in the liquid, free-choice formulations described in paragraph (e)(3)(iv)(B) of this section. Free-choice cattle feeds containing selenium must comply with published regulations (*see* 21 CFR 573.920).

[2] The labeling for the liquid free-choice Type C medicated feed must bear an expiration date of 12 weeks after the date of manufacture.
[3] The percentage of cane molasses and water in the formulation may be adjusted as needed to bring the brix value of the molasses to the industry standard of 79.5 brix.
[4] The contents of any added vitamin and trace mineral may be varied; however, they should be comparable to those used by the manufacturer for other free-choice cattle feeds.

(*2*) *Indications for use.* As in paragraph (e)(3)(i) of this section.

(*3*) *Limitations.* Feed a total of 5 mg of fenbendazole per kg (2.27 mg/lb) of body weight to cattle over a 3- to 6-day period. Milk taken during treatment and for 60 hours after the last treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 13 days following last treatment with this drug product. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves.

(4) *Horses.*

Fenbendazole grams per ton	Indications for use	Limitations	Sponsor
(i) 4,540	5 mg/kg body weight (2.27 mg/lb) for the control of large strongyles (*Strongylus edentatus, S. equinus, S. vulgaris, Triodontophorus* spp.), small strongyles (*Cyathostomum* spp., *Cylicocyclus* spp., *Cylicostephanus* spp.), and pinworms (*Oxyuris equi*); 10 mg/kg body weight (4.54 mg/lb) for the control of ascarids (*Parascaris equorum*).	Feed at the rate of 0.1 lb of feed per 100 lb of body weight to provide 2.27 mg fenbendazole/lb of body weight in a 1-day treatment or 0.2 lb of feed per 100 lb of body weight to provide 4.54 mg fenbendazole/lb of body weight in a 1-day treatment. All horses must be eating normally to ensure that each animal consumes an adequate amount of the medicated feed. Do not use in horses intended for human consumption.	000061
(ii) [Reserved]			

(5) *Zoo and wildlife animals.*

Species/Class	Fenbendazole grams per ton	Indications for use	Limitations	Sponsor
(i) Feral swine (*Sus scrofa*):.	90 to 325	For the treatment and control of kidney worm (*Stephanurus dentatus*), roundworm (*Ascaris suum*), nodular worm (*Oesophagostomum dentatum*).	Use as a complete feed at a rate to provide 3 mg/kg/day for 3 consecutive days. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.	000061
(ii) Ruminants (subfamily Antilopinae, Hippotraginae, Caprinae).	50 to 300	For the treatment and control of small stomach worm (*Trichostrongylus* spp.), thread necked intestinal worm (*Nematodirus* spp.), barberpole worm (*Haemonchus* spp.), whipworm (*Trichuris* spp.).	Use as a complete feed at a rate to provide 2.5 mg/kg/day for 3 consecutive days. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.	000061
(iii) Rocky mountain bighorn sheep (*Ovis c. canadensis*).	375 to 1,000	For the treatment and control of *Protostrongylus* spp..	Use as a complete feed at a rate to provide 10 mg/kg/day for 3 consecutive days. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season.	000061

* * * * *

§ 558.633 [Amended]

■ 42. In § 558.633, in paragraph (d)(3), remove the first sentence.

Dated: September 20, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022–20836 Filed 9–28–22; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 300

[TD 9966]

RIN 1545–BQ17

User Fees Relating to Enrolled Agents and Enrolled Retirement Plan Agents

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Final regulations.

SUMMARY: These final regulations amend existing regulations relating to user fees for enrolled agents and enrolled retirement plan agents. The final regulations increase the renewal user fee for enrolled retirement plan agents from $67 to $140. In addition, the final regulations increase both the enrollment and renewal of enrollment user fees for enrolled agents from $67 to $140. These regulations affect individuals who are or apply to become enrolled agents and individuals who are enrolled retirement plan agents. The Independent Offices Appropriation Act of 1952 authorizes charging user fees.

DATES:

Effective date: These regulations are effective October 31, 2022.

Applicability date: For the date of applicability, see §§ 300.5(d), 300.6(d), and 300.09(d).

FOR FURTHER INFORMATION CONTACT: Mark Shurtliff at (202) 317–6845 (not a toll-free number).

SUPPLEMENTARY INFORMATION:

Background

This document contains amendments to the regulations in 26 CFR part 300—User Fees. On March 1, 2022, a notice of proposed rulemaking (REG–114209–21) and notice of public hearing was published in the **Federal Register** (87 FR 11366). The document proposed amending the regulations relating to the user fees for enrolled agents and enrolled retirement plan agents. The document proposed increasing the amount of the renewal user fee for enrolled retirement plan agents from $67 to $140. In addition, the document proposed increasing both the enrollment and renewal of enrollment user fees for enrolled agents from $67 to $140. The document contains a detailed explanation of the legal background and user fee calculations regarding the amendments to these regulations.

Six comments responding to the notice of proposed rulemaking were received, including comments from the National Association of Enrolled Agents (NAEA). On May 3, 2022, representatives from the NAEA, Department of the Treasury (Treasury Department), the IRS, and the Small Business Administration (SBA), held a teleconference to listen to NAEA's comments about the proposed rulemaking. In addition, two requests to speak at the scheduled public hearing were received. A public hearing was held on May 11, 2022. After consideration of the written comments, teleconference comments, and testimony at the public hearing, the Treasury Department and the IRS have decided to adopt without modification the regulations proposed by the notice of proposed rulemaking.

Summary of Comments

The six comments submitted in response to the notice of proposed rulemaking and a summary of the teleconference comments are available at *www.regulations.gov* or upon request. Some of the comments that were submitted did not seek modification or clarification of the user fee as set forth in the proposed regulations. One commenter expressed concern with how the special enrollment examination for enrolled agents (EA SEE) is being administered. The commenter also recommended using the user fees in these regulations to provide resources for tax professionals that would improve the service they provide to their clients. The user fees in these regulations are not used by the Treasury Department or the IRS to administer the EA SEE, or to provide resources for tax professionals that improve the service they provide to their clients. Therefore, comments regarding the EA SEE and additional resources identified by the commenter are outside the scope of these regulations. Another commenter suggested that the IRS should raise the amount of the user fee to apply for or renew a preparer tax identification number (PTIN) in order to (1) lower the cost of user fees relating to enrolled agents and (2) encourage more individuals to become enrolled agents. These regulations do not relate to the PTIN user fee or the PTIN program. Therefore, comments regarding the PTIN program and related user fees are outside the scope of these regulations. Finally, one commenter suggested that it is inconsistent for the IRS to charge user fees in order to administer the enrollment and renewal of enrollment program but not charge user fees for other programs (for example, participation in the Annual Filing Season Program). Again, comments regarding programs other than the enrollment and renewal of enrollment program are outside the scope of these regulations. The summary of comments below addresses those comments that make recommendations concerning or seeking clarification of the user fees set forth in the proposed regulations relating to the user fees for enrolled agents and enrolled retirement plan agents.

A. Amount of User Fees

Four commenters expressed concern with the overall amount of the proposed enrollment and renewal of enrollment user fees and requested information regarding why the user fees are required.

The Independent Offices Appropriation Act of 1952 (IOAA) (31 U.S.C. 9701) authorizes each agency to promulgate regulations establishing the charge for services provided by the agency. The IOAA states that the services provided by an agency should be self-sustaining to the extent possible. 31 U.S.C. 9701(a). The IOAA provides that user fee regulations are subject to policies prescribed by the President, which are currently set forth in the Office of Management and Budget (OMB) Circular A–25 (OMB Circular), 58 FR 38142 (July 15, 1993).

Section 6a(1) of OMB Circular A–25 states that when a service offered by a Federal agency provides special benefits to identifiable recipients beyond those accruing to the general public, the agency should establish a user fee to recover the full cost of providing the service. An agency that seeks to impose a user fee for government-provided services must calculate the full cost of providing those services.

In accordance with OMB Circular A–25, the IRS Return Preparer Office (RPO) completed its 2021 biennial review of the enrollment and renewal of enrollment user fees associated with enrolled agents and enrolled retirement plan agents. As discussed in the notice of proposed rulemaking, during its review the RPO took into account the increase in labor, benefits, and overhead costs incurred in connection with providing enrollment services to individuals who enroll or renew